Clinical trialNCT00377572CompletedPhase 4Interventional

Inner-City Anti-IgE Therapy for Asthma

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment419Asthma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to find out if adding omalizumab to standard asthma treatment results in a safer, more effective, and longer lasting asthma treatment strategy than standard treatment alone, in inner-city children with mild to severe asthma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Andrew Liu, MD
National Jewish Health
Principal Investigator
clinicaltrials.gov ↗
George T. O'Connor, MD, MS
Boston University
Principal Investigator
clinicaltrials.gov ↗
Jacqueline Pongracic, MD
Ann & Robert H Lurie Children's Hospital of Chicago
Principal Investigator
clinicaltrials.gov ↗
Jamen Chmiel, MD
Rainbow Babies and Children's Hospital
Principal Investigator
clinicaltrials.gov ↗
Meyer Kattan, MD, CM
Columbia University
Principal Investigator
clinicaltrials.gov ↗
Rebecca S. Gruchalla, MD, PhD
University of Texas Southwestern Medical Center
Principal Investigator
clinicaltrials.gov ↗
Stephen Teach, MD, MPH
Children's National Research Institute
Principal Investigator
clinicaltrials.gov ↗
Wayne Morgan, MD, CM
University of Arizona Health Sciences Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
William W. Busse, MD
University of Wisconsin, Madison
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Arizona Health Sciences Center
Tucson, Arizona, United States
National Jewish Medical and Research Center
Denver, Colorado, United States
Children'S National Medical Center
Washington D.C., District of Columbia, United States
Children'S Memorial Hospital
Chicago, Illinois, United States
Boston University School of Medicine
Boston, Massachusetts, United States
Columbia University Medical Center
New York, New York, United States
Rainbow Babies and Children'S Hospital
Cleveland, Ohio, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Omalizumab →Omalizumab placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Oct 2006
Primary completion: 31 Dec 2009
Completion: 31 Dec 2009
Last update posted: 21 Mar 2017
Registered enrollment: 419
Registry id: NCT00377572

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.